Claims for Patent: 8,093,229

Summary for Patent: 8,093,229

Title:	Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
Abstract:	Alkynyl pyrrolo [2,3-d] pyrimidines of Formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed. ##STR00001##
Inventor(s):	Kasibhatla; Srinivas Rao (San Diego, CA), Biamonte; Marco Antonio (San Diego, CA), Shi; Jiandong (San Diego, CA), Boehm; Marcus F. (San Diego, CA)
Assignee:	Conforma Therapeutics Corporation (San Diego, CA)
Application Number:	12/471,298
Patent Claims:	1. A method of treating an individual having a cancer chosen from gastric cancer, adrenocortical cancer, melanoma, and colon cancer comprising administering to said individual a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, ##STR00297## wherein: R.sup.0 is hydrogen; R.sup.1 is chloro; R.sup.2 is --NH.sub.2; R.sup.3 is substituted lower alkyl wherein the substituent on R.sup.3 is selected from --OP(O)(OH).sub.2 and --OR.sup.8 wherein R.sup.8 is selected from hydrogen, lower alkyl, and --C(O)R.sup.9 wherein R.sup.9 is selected from H, lower alkyl, --NR.sup.10R.sup.10 and --OR.sup.11, wherein each R.sup.10 is independently selected from hydrogen and lower alkyl, or R.sup.10 and R.sup.10 taken together with the N atom to which they are attached form an optionally substituted ring comprising 3-7 ring atoms, wherein, in addition to said N atom, 0-3 of the ring atoms are heteroatoms selected from O, S and N; and R.sup.11 is lower alkyl; R.sup.4 is lower alkylene; and R.sup.5 is 3,5-dimethyl-4-methoxy-pyridin-2-yl. 2. The method of claim 1, wherein R.sup.3 is --(CH.sub.2).sub.nOH, where n is 1, 2, or 3. 3. The method of claim 1, wherein R.sup.3 is --(CH.sub.2).sub.mC(R.sup.12).sub.2(CH.sub.2).sub.nOH, wherein m is 0, 1, or 2; n is 1 or 2; and each R.sup.12 is independently hydrogen or lower alkyl. 4. The method of claim 1, wherein R.sup.3 is lower alkyl substituted with the group --OP(O)(OH).sub.2. 5. The method of claim 1, wherein R.sup.4 is --CH.sub.2--. 6. The method of claim 1, wherein the compound of Formula I is selected from compounds of the formula: ##STR00298## ##STR00299## ##STR00300## ##STR00301## ##STR00302## 7. The method of claim 1, wherein the compound of Formula I is of the formula: ##STR00303## 8. The method of claim 1, wherein the compound of Formula I is of the formula: ##STR00304## 9. The method of claim 1, wherein the compound of Formula I is of the formula: ##STR00305## 10. The method of claim 1, wherein said individual has gastric cancer. 11. The method of claim 1, wherein said individual has adrenocortical cancer. 12. The method of claim 1, wherein said individual has melanoma. 13. The method of claim 1, wherein said individual has colon cancer. 14. The method of claim 1, further comprising administering at least one therapeutic agent selected from cytotoxic agents, anti-angiogenesis agents, and anti-neoplastic agents. 15. The method of claim 14, wherein the at least one anti-angiogenesis agent is selected from VEGF receptor inhibitors. 16. The method of claim 14, wherein the at least one anti-angiogenesis agent is selected from angiostatin and endostatin. 17. The method of claim 14, wherein the at least one anti-neoplastic agent is selected from alkylating agents, anti-metabolites, epidophyllotoxins, anti-neoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, hormonal/anti-hormonal therapeutic agents, and haematopoietic growth factors. 18. The method of claim 14, wherein the at least one anti-neoplastic agent is selected from anthracyclines, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, epothilones, discodermolide, pteridines, diynenes and podophyllotoxins. 19. The method of claim 14, wherein the at least one anti-neoplastic agent is selected from paclitaxel and gemcitabine. 20. The method of claim 14, wherein the at least one anti-neoplastic agent is selected from carminomycin, daunorubicin, aminopterin, methotrexate, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, teniposide, melphalan, vinblastine, vincristine, leuorosidine, vindesine, leurosine, estramustine, carboplatin, cyclophosphamide, bleomycin, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, edatrexate trimetrexate, dacarbazine, L-asparaginase, camptothecin, topotecan, bicalutamide, flutamide, leuprolide, interferons, and interleukins.

Details for Patent 8,093,229

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-03-30